RT Journal Article
SR Electronic
T1 A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228015
DO 10.1101/2020.11.09.20228015
A1 Demichev, Vadim
A1 Tober-Lau, Pinkus
A1 Nazarenko, Tatiana
A1 Thibeault, Charlotte
A1 Whitwell, Harry
A1 Lemke, Oliver
A1 Röhl, Annika
A1 Freiwald, Anja
A1 Szyrwiel, Lukasz
A1 Ludwig, Daniela
A1 Correia-Melo, Clara
A1 Helbig, Elisa T.
A1 Stubbemann, Paula
A1 Grüning, Nana-Maria
A1 Blyuss, Oleg
A1 Vernardis, Spyros
A1 White, Matthew
A1 Messner, Christoph B.
A1 Joannidis, Michael
A1 Sonnweber, Thomas
A1 Klein, Sebastian J.
A1 Pizzini, Alex
A1 Wohlfarter, Yvonne
A1 Sahanic, Sabina
A1 Hilbe, Richard
A1 Schaefer, Benedikt
A1 Wagner, Sonja
A1 Mittermaier, Mirja
A1 Machleidt, Felix
A1 Garcia, Carmen
A1 Ruwwe-Glösenkamp, Christoph
A1 Lingscheid, Tilman
A1 de Jarcy, Laure Bosquillon
A1 Stegemann, Miriam S.
A1 Pfeiffer, Moritz
A1 Jürgens, Linda
A1 Denker, Sophy
A1 Zickler, Daniel
A1 Enghard, Philipp
A1 Zelezniak, Aleksej
A1 Campbell, Archie
A1 Hayward, Caroline
A1 Porteous, David J.
A1 Marioni, Riccardo E.
A1 Uhrig, Alexander
A1 Müller-Redetzky, Holger
A1 Zoller, Heinz
A1 Löffler-Ragg, Judith
A1 Keller, Markus A.
A1 Tancevski, Ivan
A1 Timms, John F.
A1 Zaikin, Alexey
A1 Hippenstiel, Stefan
A1 Ramharter, Michael
A1 Witzenrath, Martin
A1 Suttorp, Norbert
A1 Lilley, Kathryn
A1 Mülleder, Michael
A1 Sander, Leif Erik
A1 ,
A1 Ralser, Markus
A1 Kurth, Florian
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228015.abstract
AB COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. There is an urgent need for predictive markers that can guide clinical decision-making, inform about the effect of experimental therapies, and point to novel therapeutic targets. Here, we characterize the time-dependent progression of COVID-19 through different stages of the disease, by measuring 86 accredited diagnostic parameters and plasma proteomes at 687 sampling points, in a cohort of 139 patients during hospitalization. We report that the time-resolved patient molecular phenotypes reflect an initial spike in the systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution and immunomodulation. Further, we show that the early host response is predictive for the disease trajectory and gives rise to proteomic and diagnostic marker signatures that classify the need for supplemental oxygen therapy and mechanical ventilation, and that predict the time to recovery of mildly ill patients. In severely ill patients, the molecular phenotype of the early host response predicts survival, in two independent cohorts and weeks before outcome. We also identify age-specific molecular response to COVID-19, which involves increased inflammation and lipoprotein dysregulation in older patients. Our study provides a deep and time resolved molecular characterization of COVID-19 disease progression, and reports biomarkers for risk-adapted treatment strategies and molecular disease monitoring. Our study demonstrates accurate prognosis of COVID-19 outcome from proteomic signatures recorded weeks earlier.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021688Funding StatementThis work was supported by the Berlin University Alliance (501_Massenspektrometrie, 501_Linklab, 112_PreEP_Corona_Ralser), by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the BMBF/DLR Projekttraeger (01KI20160A, 01ZX1604B, 01KI20337, 01KX2021), Charite-BIH Centrum fuer Therapieforschung (BIH_PA_covid-19_Ralser), the BBSRC (BB/N015215/1, BB/N015282/1), the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), and the Wellcome Trust (FC001134 and IA 200829/Z/16/Z). The work was further supported by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass spectrometry in Systems Medicine (MSCoresys), under grant agreement 031L0220A. Leif Erik Sander is supported by the German Research Foundation (DFG, SFB-TR84 114933180) and by the Berlin Institute of Health (BIH), which receives funding from the Ministry of Education and Research (BMBF). Martin Witzenrath is supported by grants from the German Research Foundation, SFB-TR84 C06 and C09, by the German Ministry of Education and Research (BMBF) in the framework of the CAPSyS (01ZX1304B), CAPSyS-COVID (01ZX1604B), SYMPATH (01ZX1906A) and PROVID project (01KI20160A) and by the Berlin Institute of Health (CM-COVID). Stefan Hippenstiel is supported by the German Research Foundation (DFG, SFB-TR84 A04 and B06), and the BMBF (PROVID, and project 01KI2082). Norbert Suttorp is supported by grants from the German Research Foundation, SFB-TR84 C09 und Z02, by the German Ministry of Education and Research (BMBF) in the framework of the PROGRESS 01KI07114. The study was further supported by Wellcome Trust (200829/Z/16/Z). The Generation Scotland study received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006), and is now supported by the Wellcome Trust (216767/Z/19/Z). Archie Campbell is funded by HDR UK and the Wellcome Trust (216767/Z/19/Z). Caroline Hayward is supported by an MRC University Unit Programme Grant (MC_UU_00007/10) (QTL in Health and Disease). Riccardo Marioni is supported by an Alzheimer's Research UK project grant (ARUK-PG2017B-10). H. Whitwell, JF. Timms, A. Zaikin and T. Nazarenko are supported by a Medical Research Council grant (MR/R02524X/1) and H. Whitwell, A. Zaikin and O. Blyuss by the Ministry of Science and Higher Education agreement No. 075-15-2020-808. H. Whitwell is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). J. Timms is supported by the National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Mirja Mittermaier is a participant in the BIH-Charite Digital Clinician Scientist Program funded by the Charite Universitaetsmedizin Berlin, the Berlin Institute of Health, and the German Research Foundation (DFG). Markus A. Keller is supported by the Austrian Science Funds (FWF; P33333) and the Austrian Research Promotion Agency (FFG, #878654).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Pa-COVID-19 study was approved by the ethics committee of Charite - Universitaetsmedizin Berlin (EA2/066/20) and conducted in accordance with the Declaration of Helsinki and guidelines of Good Clinical Practice (ICH 1996). The study at the University Hospital of Innsbruck was approved by the local ethics research committee EK-Nr. 1107/2020, and EK-Nr. 1103/2020 for follow-up.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request